Banner - Reimbursement & Patient Savings

To better serve your patients

Insurance verification

Insurance verifications

  • Help providers verify payer coverage and reimbursement policies for Injectafer. Reimbursement specialists will determine patient's benefits level and discuss potential billing options with patient consent

Billing and coding assistance

  • Assist providers with the proper completion of claim forms to facilitate appropriate reimbursement

Please note: Injectafer has a unique J code: J1439

Please note: Injectafer has a unique J code: J1439

Download the Reimbursement Brochure

Download the Billing and Coding Brochure

Claims appeals

  • Support providers in appealing denied claims or inadequate reimbursement for Injectafer
  • Help track claims for administration services, including regular follow-up with payers to facilitate reimbursement. If a claim is denied, our program staff is available to coordinate the appeals process through the development of letters of medical necessity and coverage appeal request letters

Download the Reimbursement Brochure

Download the INJECT Checklist

Our commitment to your patients

Our commitment to your patients

over 90% of commercial patients have access to Injectafer*

75% of commercially covered patients have $0 co-pay

over 95% of patients receiving Medicare have access to Injectafer*

*Data on file.  DRG SPARC Database (October 2016-September 2017).

*Data on file.
DRG SPARC Database (October 2016-September 2017).

Code with accuracy

Code with accuracy

Note that Injectafer prescriptions require a primary ICD-10-CM code for IDA as well as a secondary code for the underlying condition causing IDA

Injectafer has a product-specific J-code: J1439
National Drug Code (NDC): 00517-0650-01

Patient information will be kept strictly confidential at all times.

Every attempt is made to provide accurate, up-to-date information. The IV Iron Reimbursement Hotline cannot guarantee successful reimbursement.

This information is not intended to provide legal, medical, or other professional advice. This information is provided as reference only. Daiichi Sankyo, Inc. makes no representations or guarantees regarding the completeness or accuracy of this information and has no obligation to update this information to reflect changes in laws that may affect reimbursement for Injectafer. For assistance with legal or medical issues, you are urged to consult a qualified professional.

Gradient Bar links- reimbursement & savings

Patient Savings

PATIENT SAVINGS

Important Safety Information

INDICATIONS

Injectafer® (ferric carboxymaltose injection) is an iron replacement product indicated for the treatment of iron deficiency anemia (IDA) in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, and in adult patients with non-dialysis dependent chronic kidney disease.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATIONS

Injectafer is contraindicated in patients with hypersensitivity to Injectafer or any of its inactive components.

WARNINGS AND PRECAUTIONS

Serious hypersensitivity reactions, including anaphylactic-type reactions, some of which have been life-threatening and fatal, have been reported in patients receiving Injectafer. Patients may present with shock, clinically significant hypotension, loss of consciousness, and/or collapse. Monitor patients for signs and symptoms of hypersensitivity during and after Injectafer administration for at least 30 minutes and until clinically stable following completion of the infusion. Only administer Injectafer when personnel and therapies are immediately available for the treatment of serious hypersensitivity reactions.In clinical trials, serious anaphylactic/anaphylactoid reactions were reported in 0.1% (2/1775) of subjects receiving Injectafer. Other serious or severe adverse reactions potentially associated with hypersensitivity which included, but were not limited to, pruritus, rash, urticaria, wheezing, or hypotension were reported in 1.5% (26/1775) of these subjects.

In clinical studies, hypertension was reported in 3.8% (67/1775) of subjects. Transient elevations in systolic blood pressure, sometimes occurring with facial flushing, dizziness, or nausea were observed in 6% (106/1775) of subjects. These elevations generally occurred immediately after dosing and resolved within 30 minutes. Monitor patients for signs and symptoms of hypertension following each Injectafer administration.

In the 24 hours following administration of Injectafer, laboratory assays may overestimate serum iron and transferrin bound iron by also measuring the iron in Injectafer.

ADVERSE REACTIONS

In two randomized clinical studies, a total of 1775 patients were exposed to Injectafer, 15 mg/kg of body weight, up to a single maximum dose of 750 mg of iron on two occasions, separated by at least 7 days, up to a cumulative dose of 1500 mg of iron. Adverse reactions reported by ≥2% of Injectafer-treated patients were nausea (7.2%); hypertension (3.8%); flushing/hot flush (3.6%); blood phosphorus decrease (2.1%); and dizziness (2.0%).

The following serious adverse reactions have been most commonly reported from the post-marketing spontaneous reports: urticaria, dyspnea, pruritus, tachycardia, erythema, pyrexia, chest discomfort, chills, angioedema, back pain, arthralgia, and syncope.

To report adverse events, please contact American Regent at 1-800-734-9236. You may also contact the FDA at www.fda.gov/medwatch or 1-800-FDA-1088.

Please see Full Prescribing Information.